Skip to Main Content

Author Details

Nicholas Erho
GenomeDx Biosciences Inc.
2012
63
37
PMIDPaper TitleJournal TitlePublished Year
30367117Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.Prostate Cancer Prostatic Dis2019
30224344Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.Clin Cancer Res2019
31206668Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.J Pathol2019
31125117Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.Int J Cancer2019
30321406The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.J Natl Cancer Inst2019
28753844Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.Eur Urol Focus2018
29853306The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.Eur Urol2018
30108099Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.Cancer Epidemiol Biomarkers Prev2018
28330676Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.Eur Urol2018
28400167Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.Eur Urol2018
29729848Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.EBioMedicine2018
29511883Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.J Cancer Res Clin Oncol2018
29760221Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.Clin Cancer Res2018
29757368The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.Gigascience2018
27460352Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.Eur Urol2017
28415728Lipid degradation promotes prostate cancer cell survival.Oncotarget2017
28390739Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Eur Urol2017
28140459Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.Cancer2017
28107602Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.BJU Int2017
28494073Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.JAMA Oncol2017
28145883Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.Oncotarget2017
28092670Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.Oncogene2017
28341589Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.J Mol Diagn2017
29132337Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.BMC Cancer2017
28916652LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.Cancer Res2017
28881605Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.Oncotarget2017
28591577Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Cell Rep2017
28899973TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Clin Cancer Res2017
27801901Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.Prostate Cancer Prostatic Dis2017
26058959Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.Eur Urol2016
29188191Prostate cancer radiomics and the promise of radiogenomics.Transl Cancer Res2016
26631616The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.Clin Cancer Res2016
26446945Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.Clin Cancer Res2016
26443432Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.Eur Urol2016
27713863Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.Urol Case Rep2016
27743920Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.Lancet Oncol2016
27302169Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.Cancer Res2016
27238617SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.J Urol2016
27438142Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Oncotarget2016
26746117Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.JAMA Oncol2016
27014907Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.Oncotarget2016
26771938AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.Prostate2016
27105761Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.J Urol2016
26945428Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.J Mol Diagn2016
25762434Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence.BJU Int2015
26294211Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.Cancer Res2015
26041878Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.Oncotarget2015
25900404Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.Biol Cell2015
25964175Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Eur Urol2015
25986914High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.Prostate Cancer Prostatic Dis2015
  • 1 - 50 of 63

Recommended Authors

Toronto Metropolitan University
Career Start Year 2018
Number of shared co-authors 9
GenomeDx Biosciences Inc.
Career Start Year 2017
Number of shared co-authors 25
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 16
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 26
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 12
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 17
Oncology R&D
Career Start Year 2013
Number of shared co-authors 18
University of California los angeles
Career Start Year 2011
Number of shared co-authors 59
Erasmus Medical Center
Career Start Year 2011
Number of shared co-authors 10
University of British Columbia
Career Start Year 2011
Number of shared co-authors 38
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 27
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 56
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 17
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 25
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 9
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 4
McGill University and the Research Institute of the McGill University Health Centre
Career Start Year 2004
Number of shared co-authors 7
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 13
University of Cambridge
Career Start Year 2003
Number of shared co-authors 24
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 33
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Career Start Year 2003
Number of shared co-authors 19
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 26
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 35
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 20
University College London
Career Start Year 1999
Number of shared co-authors 19
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 42
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 26
University of California
Career Start Year 1996
Number of shared co-authors 20
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 39
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 23

Collaborators

Veracyte Inc.
Co-authored papers 62
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 29
Mayo Clinic
Co-authored papers 29
Northwestern University Feinberg School of Medicine
Co-authored papers 28
Northwestern University
Co-authored papers 27
GenomeDx Biosciences Inc.
Co-authored papers 24
Thomas Jefferson University Hospital
Co-authored papers 22
Cleveland Clinic
Co-authored papers 18
UCSF Medical Center-Mount Zion
Co-authored papers 17
School of Clinical Medicine, University of Hong Kong, Queen Mary Hospital
Co-authored papers 11
Center for Epigenetics, Van Andel Research Institute
Co-authored papers 8
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 7
Johns Hopkins University School of Medicine
Co-authored papers 7
Cedars-Sinai Medical Center
Co-authored papers 7
Johns Hopkins University School of Medicine
Co-authored papers 6
University of British Columbia
Co-authored papers 6
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 6
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 5
University of British Columbia
Co-authored papers 4
University of Michigan Medical School.
Co-authored papers 4
Center for Comparative Medicine, Baylor College of Medicine
Co-authored papers 4
University of British Columbia
Co-authored papers 4
University of British Columbia
Co-authored papers 3
Weill-Cornell School of Medicine
Co-authored papers 3
University Health Network, University of Toronto
Co-authored papers 3
University of California los angeles
Co-authored papers 3
Mayo Clinic
Co-authored papers 3
Vanderbilt University Medical Center
Co-authored papers 3
University of British Columbia
Co-authored papers 3
University of Bern
Co-authored papers 3